{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:13:48Z","timestamp":1793812428020,"version":"4.6.1"},"reference-count":32,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Individuals classified as having very high fracture risk remain vulnerable to imminent fractures even when treated with antiresorptive therapies. This meta-analysis evaluated whether initiating treatment with anabolic agents, including teriparatide, abaloparatide, and romosozumab, provides superior fracture protection in this high-risk population. Materials and Methods: A systematic review and meta-analysis of randomized controlled trials was conducted following PRISMA standards. Eligible studies included adults at very high fracture risk, defined by recent or multiple fragility fractures or markedly low bone mineral density, who received anabolic therapy as initial treatment compared with placebo or antiresorptive agents. Outcomes of interest were new vertebral, non-vertebral, hip, and clinical fractures. Effect estimates were pooled using random-effects models. Results: Six randomized trials encompassing 17,872 participants were analyzed. Initiation with anabolic therapy was associated with a marked reduction in incident vertebral fractures. The labeled pooled summary estimate for vertebral fractures was 0.43 (95% confidence interval 0.34\u20130.54). Significant risk reductions were also observed for clinical fractures (hazard ratio 0.62, 95% confidence interval 0.51\u20130.75), non-vertebral fractures (pooled effect estimate 0.71, 95% confidence interval 0.59\u20130.85), and hip fractures (risk ratio 0.65, 95% confidence interval 0.45\u20130.96). Exploratory subgroup analyses suggested greater vertebral fracture protection versus placebo and persistent benefit versus active antiresorptive comparators. Sequential therapy using an anabolic agent followed by an antiresorptive reduced spinal fracture risk by approximately half. Considerable heterogeneity was noted for vertebral fracture outcomes. Conclusions: Starting osteoporosis treatment with anabolic agents results in faster and more-pronounced fracture risk reduction across all major fracture categories in patients at very high fracture risk. These findings support a shift toward anabolic-first treatment sequencing in this particularly vulnerable group.<\/jats:p>","DOI":"10.3390\/medicina62040687","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T04:10:27Z","timestamp":1775448627000},"page":"687","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Anabolic-First Strategy in Osteoporosis: A Systematic Review and Meta-Analysis of Fracture Outcomes in Patients at Very High Fracture Risk"],"prefix":"10.3390","volume":"62","author":[{"given":"Valerio","family":"Cipolloni","sequence":"first","affiliation":[{"name":"Department of Orthopaedics, A.O.U. \u201cVanvitelli\u201d University Hospital, \u201cLuigi Vanvitelli\u201d University, Via del Sole 10, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bonifacio","sequence":"additional","affiliation":[{"name":"ASL Roma 4, 00053 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4918-7393","authenticated-orcid":false,"given":"Syeda Maryam","family":"Hassny","sequence":"additional","affiliation":[{"name":"Institute of Administrative Sciences, Punjab University (PU), Lahore 54000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Melara","sequence":"additional","affiliation":[{"name":"School of Biosciences, The University of Sheffield, Sheffield S10 2TN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2691-5383","authenticated-orcid":false,"given":"Linda","family":"Lucchetti","sequence":"additional","affiliation":[{"name":"ASL Roma 4, 00053 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5286-2550","authenticated-orcid":false,"given":"Martina","family":"Gentile","sequence":"additional","affiliation":[{"name":"Local Health Rheumatology Unit, San Paolo Hospital of Civitavecchia, ASL Roma 4, 00053 Civitavecchia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Conforti","sequence":"additional","affiliation":[{"name":"ASL Roma 4, 00053 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Van Oostwaard, M. (2018). Osteoporosis and the Nature of Fragility Fracture: An Overview. Perspectives in Nursing Management and Care for Older Adults, Springer.","DOI":"10.1007\/978-3-319-76681-2_1"},{"key":"ref_2","first-page":"609","article-title":"Global prevalence of osteoporosis according to the World Health Organization diagnostic criteria: A systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"Arch. Osteoporos."},{"key":"ref_3","unstructured":"World Health Organization (2021). Fragility Fractures: Global Burden and Epidemiology, WHO."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos. Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40520-020-01708-8","article-title":"Role of bone-forming agents in the management of osteoporosis","volume":"33","author":"McClung","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Anabolic therapies for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2147\/IJWH.S315184","article-title":"Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives","volume":"14","author":"Lim","year":"2022","journal-title":"Int. J. Womens Health"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs. placebo on new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): A multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/os.13136","article-title":"Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis through a Grade Analysis of Evidence","volume":"13","author":"Tian","year":"2021","journal-title":"Orthop. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"707","DOI":"10.20945\/2359-3997000000566","article-title":"Anabolic therapy for osteoporosis: Update on efficacy and safety","volume":"66","author":"Bandeira","year":"2022","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00198-023-06870-z","article-title":"Previous fracture and subsequent fracture risk: A meta-analysis to update FRAX","volume":"34","author":"Kanis","year":"2023","journal-title":"Osteoporos. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): A randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","article-title":"Treatment sequence for osteoporosis","volume":"30","author":"Cosman","year":"2024","journal-title":"Endocr. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A 24-Month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: Results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","article-title":"Recommendations for the conduct of economic evaluations in osteoporosis: Outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation","volume":"30","author":"Hiligsmann","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40520-024-02921-5","article-title":"Romosozumab adverse event profile: A pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023","volume":"37","author":"Liu","year":"2025","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0889-8529(05)70009-8","article-title":"Osteoporosis in men","volume":"27","author":"Orwoll","year":"1998","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","article-title":"Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies","volume":"116","author":"Langdahl","year":"2018","journal-title":"Bone"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11914-017-0410-z","article-title":"The Trabecular Bone Score (TBS) Complements DXA and the FRAX as a Fracture Risk Assessment Tool in Routine Clinical Practice","volume":"15","author":"Hans","year":"2017","journal-title":"Curr. Osteoporos. Rep."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/687\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T04:56:21Z","timestamp":1775451381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["medicina62040687"],"URL":"https:\/\/doi.org\/10.3390\/medicina62040687","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}